Sairiyo is currently focused on advancing the clinical
development of cepharanthine to treat rare forms of
cancer.
160 peer reviewed studies show benefit in treating cancer alone, or in combination with front line chemotherapeutics
Approved for more than 70 years by Japanese Regulatory body
Has hampered broad use in oncology
Secured exclusive rights to a highly bioavailable oral formulation of cepharanthine
